SIMILAR PATTERNS OF AMINO ACIDS FOR 6HD4_A_STIA604_0

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1gng	GLYCOGEN SYNTHASE KINASE-3 BETA (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 70 ALA A 83 LYS A 85 GLU A 97 VAL A 110 LEU A 188	None	0.59A	6hd4A-1gngA: 20.4	6hd4A-1gngA: 12.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	VAL A 209 ALA A 220 GLU A 236 MET A 240 VAL A 249 ILE A 264 THR A 266 LEU A 321	None	0.70A	6hd4A-1k9aA: 26.8	6hd4A-1k9aA: 16.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	VAL A 209 ALA A 220 LYS A 222 GLU A 236 MET A 240 VAL A 249 ILE A 264 THR A 266	None	0.59A	6hd4A-1k9aA: 26.8	6hd4A-1k9aA: 16.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	7	ALA A 606 LYS A 608 MET A 629 VAL A 638 LEU A 731 ALA A 741 ASP A 742	None	1.16A	6hd4A-1lufA: 34.0	6hd4A-1lufA: 31.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	7	VAL A 588 ALA A 606 LYS A 608 VAL A 638 LEU A 731 ALA A 741 ASP A 742	None	0.86A	6hd4A-1lufA: 34.0	6hd4A-1lufA: 31.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	11	VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 ILE A 312 VAL A 318 ILE A 332 THR A 334 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.70A	6hd4A-1opkA: 36.8	6hd4A-1opkA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 603 ALA A 621 GLU A 640 VAL A 654 THR A 670 LEU A 799 ASP A 810	STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-3.6A) STI A 3 (-4.3A) STI A 3 (-3.2A) STI A 3 (-4.4A) STI A 3 (-3.9A)	0.54A	6hd4A-1t46A: 33.7	6hd4A-1t46A: 14.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 352 ALA A 367 LYS A 369 GLU A 386 MET A 390 VAL A 399 LEU A 468	STU A 100 (-4.8A) STU A 100 (-3.2A) STU A 100 ( 4.7A) None None None STU A 100 (-4.5A)	0.60A	6hd4A-1u59A: 29.8	6hd4A-1u59A: 15.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zrz	PROTEIN KINASE C, IOTA (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	VAL A 259 ALA A 272 LYS A 274 GLU A 293 VAL A 307 LEU A 376 ASP A 387	BI1 A1000 (-4.2A) BI1 A1000 (-3.4A) BI1 A1000 (-3.5A) BI1 A1000 ( 4.9A) BI1 A1000 (-4.4A) BI1 A1000 (-4.8A) BI1 A1000 (-4.5A)	1.06A	6hd4A-1zrzA: 20.0	6hd4A-1zrzA: 14.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLU X 54 MET X 58 VAL X 67 ILE X 80 THR X 82 ALA X 147 ASP X 148	STU X 902 ( 4.4A) None None None STU X 902 (-4.1A) STU X 902 ( 4.1A) STU X 902 (-3.6A)	0.99A	6hd4A-2dq7X: 31.5	6hd4A-2dq7X: 17.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	VAL X 25 ALA X 37 LYS X 39 GLU X 54 MET X 58 VAL X 67 ILE X 80 THR X 82 LEU X 137 ALA X 147	STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-3.1A) STU X 902 ( 4.4A) None None None STU X 902 (-4.1A) STU X 902 (-4.4A) STU X 902 ( 4.1A)	0.73A	6hd4A-2dq7X: 31.5	6hd4A-2dq7X: 17.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 170 ALA A 184 GLU A 201 ILE A 208 VAL A 220 ILE A 234 LEU A 290 ALA A 319	None	0.72A	6hd4A-2eu9A: 21.1	6hd4A-2eu9A: 13.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 170 ALA A 184 LYS A 186 GLU A 201 ILE A 208 ILE A 234 LEU A 290 ALA A 319	None	0.79A	6hd4A-2eu9A: 21.1	6hd4A-2eu9A: 13.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	VAL A 281 ALA A 293 LYS A 295 VAL A 323 ILE A 336 THR A 338	H8H A 534 (-4.4A) H8H A 534 (-3.2A) H8H A 534 (-3.7A) None H8H A 534 ( 4.5A) H8H A 534 (-3.1A)	0.58A	6hd4A-2h8hA: 29.7	6hd4A-2h8hA: 9.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	VAL A 281 ALA A 293 VAL A 323 ILE A 336 THR A 338 LEU A 393 ALA A 403	H8H A 534 (-4.4A) H8H A 534 (-3.2A) None H8H A 534 ( 4.5A) H8H A 534 (-3.1A) H8H A 534 (-4.5A) H8H A 534 ( 4.0A)	0.92A	6hd4A-2h8hA: 29.7	6hd4A-2h8hA: 9.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	VAL A 281 ALA A 293 LYS A 295 VAL A 323 ILE A 336 THR A 338 ALA A 403	QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None None None QUE A 1 (-3.3A) QUE A 1 ( 4.5A)	0.95A	6hd4A-2hckA: 29.2	6hd4A-2hckA: 13.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	VAL A 281 ALA A 293 VAL A 323 ILE A 336 THR A 338 LEU A 393 ALA A 403	QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None None QUE A 1 (-3.3A) QUE A 1 (-4.4A) QUE A 1 ( 4.5A)	0.95A	6hd4A-2hckA: 29.2	6hd4A-2hckA: 13.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	VAL A 259 ALA A 271 GLU A 288 MET A 292 VAL A 301 ILE A 314 THR A 316 LEU A 371 ALA A 381 ASP A 382	1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) 1BM A 499 (-3.2A) 1BM A 499 ( 3.8A) None 1BM A 499 (-3.9A) 1BM A 499 (-3.2A) 1BM A 499 (-4.4A) 1BM A 499 ( 3.7A) 1BM A 499 (-4.4A)	1.01A	6hd4A-2hk5A: 26.5	6hd4A-2hk5A: 18.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 259 ALA A 271 LYS A 273 GLU A 288 MET A 292 VAL A 301 ILE A 314 THR A 316	1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) 1BM A 499 (-3.8A) 1BM A 499 (-3.2A) 1BM A 499 ( 3.8A) None 1BM A 499 (-3.9A) 1BM A 499 (-3.2A)	0.62A	6hd4A-2hk5A: 26.5	6hd4A-2hk5A: 18.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	ALA A 269 GLU A 286 MET A 290 ILE A 293 VAL A 299 ILE A 313 THR A 315 LEU A 370 ALA A 380 ASP A 381	GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.2A) GIN A 600 (-4.5A) GIN A 600 (-4.6A) GIN A 600 (-3.8A) GIN A 600 (-3.4A) GIN A 600 (-4.7A) GIN A 600 (-3.1A) GIN A 600 (-4.9A)	0.78A	6hd4A-2hz0A: 34.3	6hd4A-2hz0A: 92.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	VAL A 256 ALA A 269 GLU A 286 MET A 290 ILE A 293 VAL A 299 ILE A 313 THR A 315 LEU A 370 ALA A 380	GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.2A) GIN A 600 (-4.5A) GIN A 600 (-4.6A) GIN A 600 (-3.8A) GIN A 600 (-3.4A) GIN A 600 (-4.7A) GIN A 600 (-3.1A)	0.59A	6hd4A-2hz0A: 34.3	6hd4A-2hz0A: 92.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 256 ALA A 269 LYS A 271 GLU A 286 MET A 290 ILE A 293 ILE A 313	GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.6A) GIN A 600 (-3.2A) GIN A 600 (-4.5A) GIN A 600 (-3.8A)	0.78A	6hd4A-2hz0A: 34.3	6hd4A-2hz0A: 92.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2j0j	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF00373 (FERM_M) PF07714 (Pkinase_Tyr)	7	ALA A 452 LYS A 454 GLU A 471 MET A 475 VAL A 484 ILE A 497 ASP A 564	4ST A1687 (-3.3A) 4ST A1687 (-3.4A) 4ST A1687 ( 4.6A) None None None 4ST A1687 (-4.7A)	0.83A	6hd4A-2j0jA: 31.7	6hd4A-2j0jA: 7.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2j0j	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF00373 (FERM_M) PF07714 (Pkinase_Tyr)	8	VAL A 436 ALA A 452 LYS A 454 GLU A 471 MET A 475 VAL A 484 ILE A 497 LEU A 553	4ST A1687 ( 4.8A) 4ST A1687 (-3.3A) 4ST A1687 (-3.4A) 4ST A1687 ( 4.6A) None None None 4ST A1687 (-4.4A)	0.70A	6hd4A-2j0jA: 31.7	6hd4A-2j0jA: 7.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	VAL A 259 ALA A 271 GLU A 288 MET A 292 VAL A 301 ILE A 314 THR A 316 LEU A 371 ALA A 381 ASP A 382	None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.6A) 1N8 A 501 ( 3.6A) None 1N8 A 501 ( 4.6A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 4.3A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.3A)	0.57A	6hd4A-2og8A: 26.1	6hd4A-2og8A: 16.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 259 ALA A 271 LYS A 273 GLU A 288 MET A 292 ILE A 314 ALA A 381 ASP A 382	None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.6A) 1N8 A 501 ( 3.6A) 1N8 A 501 ( 4.6A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.3A)	0.79A	6hd4A-2og8A: 26.1	6hd4A-2og8A: 16.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 596 ALA A 614 GLU A 633 MET A 637 VAL A 647 THR A 663 ASP A 796	None	0.93A	6hd4A-2ogvA: 22.1	6hd4A-2ogvA: 14.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 596 ALA A 614 GLU A 633 MET A 637 VAL A 647 THR A 663 LEU A 785	None	0.86A	6hd4A-2ogvA: 22.1	6hd4A-2ogvA: 14.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 838 ALA A 853 LYS A 855 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 4.6A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.58A	6hd4A-2p4iA: 12.2	6hd4A-2p4iA: 12.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 495 ALA A 515 GLU A 534 MET A 538 ILE A 541 LEU A 633 ALA A 643	None	0.63A	6hd4A-2psqA: 31.4	6hd4A-2psqA: 14.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qob	EPHRIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 635 ALA A 651 GLU A 670 MET A 674 ILE A 697 THR A 699 ASP A 764	BME A 1 (-4.9A) PTR A 701 ( 4.7A) None None None None None	1.04A	6hd4A-2qobA: 26.1	6hd4A-2qobA: 13.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2vd5	DMPK PROTEIN (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 85 ALA A 98 LYS A 100 GLU A 119 LEU A 202 ALA A 212	BI8 A1417 ( 4.7A) BI8 A1417 ( 3.8A) BI8 A1417 (-4.2A) BI8 A1417 ( 4.9A) BI8 A1417 (-4.8A) BI8 A1417 ( 4.1A)	0.59A	6hd4A-2vd5A: 19.3	6hd4A-2vd5A: 10.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xik	SERINE/THREONINE PROTEIN KINASE 25 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 34 ALA A 47 LYS A 49 GLU A 66 ILE A 93 LEU A 147 ALA A 157	J60 A1294 ( 4.9A) J60 A1294 (-3.3A) None None None J60 A1294 (-4.8A) J60 A1294 ( 4.2A)	0.82A	6hd4A-2xikA: 18.3	6hd4A-2xikA: 15.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	8	VAL A 635 ALA A 651 LYS A 653 MET A 674 ILE A 697 THR A 699 LEU A 753 ASP A 764	Q9G A1898 ( 4.7A) Q9G A1898 (-3.2A) Q9G A1898 (-4.8A) Q9G A1898 (-3.9A) Q9G A1898 ( 4.6A) Q9G A1898 (-3.5A) Q9G A1898 (-4.3A) None	0.77A	6hd4A-2xyuA: 32.4	6hd4A-2xyuA: 14.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 261 ALA A 273 GLU A 290 MET A 294 VAL A 303 THR A 319 ASP A 385	None	1.06A	6hd4A-2zv7A: 30.8	6hd4A-2zv7A: 19.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 261 ALA A 273 GLU A 290 VAL A 303 ILE A 317 THR A 319 ASP A 385	None	0.87A	6hd4A-2zv7A: 30.8	6hd4A-2zv7A: 19.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 261 ALA A 273 MET A 294 VAL A 303 THR A 319 ALA A 384 ASP A 385	None	1.08A	6hd4A-2zv7A: 30.8	6hd4A-2zv7A: 19.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 261 ALA A 273 MET A 294 VAL A 303 THR A 319 LEU A 374 ALA A 384	None	1.11A	6hd4A-2zv7A: 30.8	6hd4A-2zv7A: 19.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 261 ALA A 273 VAL A 303 ILE A 317 THR A 319 ALA A 384 ASP A 385	None	0.70A	6hd4A-2zv7A: 30.8	6hd4A-2zv7A: 19.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 261 ALA A 273 VAL A 303 ILE A 317 THR A 319 LEU A 374 ALA A 384	None	0.86A	6hd4A-2zv7A: 30.8	6hd4A-2zv7A: 19.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 492 ALA A 512 GLU A 531 MET A 535 ILE A 538 LEU A 630 ALA A 640	None C4F A 1 (-3.3A) None C4F A 1 ( 3.7A) None C4F A 1 (-4.6A) C4F A 1 (-3.6A)	0.68A	6hd4A-3c4fA: 24.7	6hd4A-3c4fA: 14.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 209 ALA A 220 GLU A 236 MET A 240 VAL A 249 ILE A 264 THR A 266 LEU A 321	None	0.70A	6hd4A-3d7uA: 26.8	6hd4A-3d7uA: 15.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 209 ALA A 220 LYS A 222 GLU A 236 MET A 240 VAL A 249 ILE A 264 THR A 266	None	0.59A	6hd4A-3d7uA: 26.8	6hd4A-3d7uA: 15.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dko	EPHRIN TYPE-A RECEPTOR 7 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	8	VAL A 647 ALA A 663 LYS A 665 GLU A 682 MET A 686 VAL A 695 ILE A 709 ASP A 776	IHZ A1001 ( 4.4A) IHZ A1001 (-3.3A) IHZ A1001 ( 4.5A) IHZ A1001 (-3.8A) IHZ A1001 (-3.5A) IHZ A1001 ( 4.9A) None IHZ A1001 (-4.8A)	0.73A	6hd4A-3dkoA: 30.4	6hd4A-3dkoA: 13.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dko	EPHRIN TYPE-A RECEPTOR 7 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 647 ALA A 663 LYS A 665 VAL A 695 ILE A 709 LEU A 765 ASP A 776	IHZ A1001 ( 4.4A) IHZ A1001 (-3.3A) IHZ A1001 ( 4.5A) IHZ A1001 ( 4.9A) None IHZ A1001 (-4.6A) IHZ A1001 (-4.8A)	0.70A	6hd4A-3dkoA: 30.4	6hd4A-3dkoA: 13.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3fme	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 67 ALA A 80 LYS A 82 VAL A 113 ILE A 127 LEU A 186	None STU A 1 (-3.4A) STU A 1 ( 4.2A) None None STU A 1 (-4.4A)	0.60A	6hd4A-3fmeA: 16.9	6hd4A-3fmeA: 16.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3gp0	MITOGEN-ACTIVATED PROTEIN KINASE 11 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 38 ALA A 51 LYS A 53 GLU A 71 THR A 106 ASP A 168	NIL A 1 ( 4.7A) NIL A 1 (-3.7A) None NIL A 1 (-3.7A) NIL A 1 (-3.3A) NIL A 1 (-4.6A)	0.53A	6hd4A-3gp0A: 21.9	6hd4A-3gp0A: 13.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 841 ALA A 859 GLU A 878 ILE A 885 VAL A 892 LEU A1029 ASP A1040	8ST A2001 ( 4.6A) 8ST A2001 ( 3.8A) 8ST A2001 (-3.7A) None 8ST A2001 ( 4.7A) None None	0.87A	6hd4A-3hngA: 32.7	6hd4A-3hngA: 12.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 841 ALA A 859 LYS A 861 GLU A 878 ILE A 885 VAL A 892 ASP A1040	8ST A2001 ( 4.6A) 8ST A2001 ( 3.8A) 8ST A2001 (-4.0A) 8ST A2001 (-3.7A) None 8ST A2001 ( 4.7A) None	0.91A	6hd4A-3hngA: 32.7	6hd4A-3hngA: 12.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3iec	SERINE/THREONINE-PRO TEIN KINASE MARK2 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	7	VAL A 67 ALA A 80 LYS A 82 MET A 104 VAL A 113 ALA A 192 ASP A 193	None	0.68A	6hd4A-3iecA: 22.3	6hd4A-3iecA: 13.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3iec	SERINE/THREONINE-PRO TEIN KINASE MARK2 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	7	VAL A 67 ALA A 80 LYS A 82 MET A 104 VAL A 113 LEU A 182 ALA A 192	None	0.73A	6hd4A-3iecA: 22.3	6hd4A-3iecA: 13.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 649 ALA A 665 GLU A 684 MET A 688 ILE A 711 THR A 713 LEU A 767	None	0.65A	6hd4A-3kulA: 31.4	6hd4A-3kulA: 11.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 649 ALA A 665 LYS A 667 GLU A 684 MET A 688 ILE A 711 THR A 713	None	0.77A	6hd4A-3kulA: 31.4	6hd4A-3kulA: 11.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	7	VAL A 218 ALA A 229 LYS A 231 GLU A 244 THR A 279 LEU A 339 ALA A 349	LDN A 1 ( 4.8A) LDN A 1 (-3.6A) None None LDN A 1 (-3.8A) LDN A 1 (-4.5A) LDN A 1 ( 3.8A)	0.77A	6hd4A-3mdyA: 24.4	6hd4A-3mdyA: 13.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	8	ALA A 576 LYS A 578 GLU A 596 MET A 600 VAL A 609 ILE A 623 THR A 625 LEU A 683	STU A 1 (-3.3A) STU A 1 (-3.5A) None None None None STU A 1 (-4.1A) STU A 1 (-4.3A)	0.73A	6hd4A-3ppzA: 28.3	6hd4A-3ppzA: 12.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	8	VAL A 565 ALA A 576 LYS A 578 MET A 600 VAL A 609 ILE A 623 THR A 625 LEU A 683	STU A 1 (-4.9A) STU A 1 (-3.3A) STU A 1 (-3.5A) None None None STU A 1 (-4.1A) STU A 1 (-4.3A)	0.75A	6hd4A-3ppzA: 28.3	6hd4A-3ppzA: 12.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 431 ALA A 443 MET A 464 VAL A 473 ILE A 487 THR A 489 LEU A 543	PP2 A 1 (-4.5A) PP2 A 1 (-3.2A) PP2 A 1 ( 4.3A) None PP2 A 1 (-3.6A) PP2 A 1 (-3.3A) PP2 A 1 (-4.6A)	0.68A	6hd4A-3sxsA: 25.0	6hd4A-3sxsA: 12.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 492 ALA A 512 LYS A 514 GLU A 531 MET A 535 ILE A 538 LEU A 630 ALA A 640	07J A 1 (-4.0A) 07J A 1 (-3.5A) 07J A 1 (-4.5A) 07J A 1 (-3.8A) 07J A 1 (-3.8A) None 07J A 1 ( 4.4A) 07J A 1 (-3.2A)	0.69A	6hd4A-3tt0A: 30.4	6hd4A-3tt0A: 13.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 848 ALA A 866 LYS A 868 GLU A 885 ILE A 892 VAL A 899 LEU A1035 ASP A1046	4TT A2001 ( 4.5A) 4TT A2001 (-3.5A) None None None None 4TT A2001 (-4.8A) None	0.77A	6hd4A-3vidA: 29.9	6hd4A-3vidA: 14.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 848 ALA A 866 LYS A 868 GLU A 885 ILE A 892 VAL A 899 LEU A1035	LEV A1201 ( 4.9A) LEV A1201 (-3.5A) None LEV A1201 (-3.7A) None None LEV A1201 (-4.8A)	0.61A	6hd4A-3wzdA: 30.7	6hd4A-3wzdA: 14.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 848 ALA A 866 GLU A 885 ILE A 892 VAL A 899 LEU A1035 ASP A1046	None B49 A2000 (-3.5A) None None B49 A2000 ( 4.6A) B49 A2000 (-4.5A) None	0.80A	6hd4A-4agdA: 32.5	6hd4A-4agdA: 14.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 50 ALA A 63 GLU A 81 VAL A 94 ILE A 108 LEU A 164 ALA A 174	XZN A1317 ( 4.7A) XZN A1317 (-3.5A) XZN A1317 (-3.9A) XZN A1317 (-4.4A) XZN A1317 (-4.4A) XZN A1317 (-4.7A) XZN A1317 ( 4.3A)	0.70A	6hd4A-4bc6A: 21.2	6hd4A-4bc6A: 16.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 50 ALA A 63 LYS A 65 ILE A 84 ILE A 108 LEU A 164 ALA A 174	XZN A1317 ( 4.7A) XZN A1317 (-3.5A) XZN A1317 (-4.1A) None XZN A1317 (-4.4A) XZN A1317 (-4.7A) XZN A1317 ( 4.3A)	1.11A	6hd4A-4bc6A: 21.2	6hd4A-4bc6A: 16.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 50 ALA A 63 LYS A 65 VAL A 94 ILE A 108 LEU A 164 ALA A 174	XZN A1317 ( 4.7A) XZN A1317 (-3.5A) XZN A1317 (-4.1A) XZN A1317 (-4.4A) XZN A1317 (-4.4A) XZN A1317 (-4.7A) XZN A1317 ( 4.3A)	0.78A	6hd4A-4bc6A: 21.2	6hd4A-4bc6A: 16.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 624 ALA A 653 LYS A 655 GLU A 672 MET A 676 THR A 701 LEU A 773 ALA A 783 ASP A 784	DI1 A1000 (-4.8A) DI1 A1000 (-3.6A) DI1 A1000 (-3.9A) DI1 A1000 (-3.8A) DI1 A1000 (-3.6A) DI1 A1000 (-3.6A) DI1 A1000 (-4.5A) DI1 A1000 (-3.7A) DI1 A1000 (-4.1A)	0.70A	6hd4A-4ckrA: 32.1	6hd4A-4ckrA: 13.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 836 ALA A 853 LYS A 855 GLU A 871 VAL A 884 LEU A 956 ALA A 966	19S A1201 (-4.4A) 19S A1201 (-3.3A) 19S A1201 (-3.5A) None None 19S A1201 (-4.5A) 19S A1201 ( 4.1A)	0.66A	6hd4A-4hviA: 29.0	6hd4A-4hviA: 12.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 486 ALA A 506 GLU A 525 MET A 529 ILE A 532 LEU A 624 ALA A 634	ACP A 801 (-4.2A) ACP A 801 (-3.3A) ACP A 801 ( 4.8A) None None ACP A 801 (-4.4A) None	0.81A	6hd4A-4k33A: 30.8	6hd4A-4k33A: 15.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 486 ALA A 506 LYS A 508 GLU A 525 MET A 529 ILE A 532	ACP A 801 (-4.2A) ACP A 801 (-3.3A) ACP A 801 (-2.7A) ACP A 801 ( 4.8A) None None	0.50A	6hd4A-4k33A: 30.8	6hd4A-4k33A: 15.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lg4	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 41 ALA A 54 GLU A 70 MET A 74 VAL A 83 LEU A 153 ALA A 163	GOL A 404 (-4.5A) GOL A 404 ( 3.1A) None None GOL A 403 (-4.1A) GOL A 403 ( 4.4A) GOL A 403 ( 3.0A)	1.13A	6hd4A-4lg4A: 17.0	6hd4A-4lg4A: 15.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 54 ALA A 67 GLU A 85 MET A 89 VAL A 99 THR A 123 LEU A 180	None SIN A 401 ( 3.7A) None None None None SIN A 401 ( 4.5A)	0.85A	6hd4A-4o38A: 19.1	6hd4A-4o38A: 14.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 54 ALA A 67 LYS A 69 GLU A 85 MET A 89 VAL A 99 THR A 123	None SIN A 401 ( 3.7A) None None None None None	0.78A	6hd4A-4o38A: 19.1	6hd4A-4o38A: 14.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	9	VAL A 22 ALA A 35 GLU A 52 MET A 56 VAL A 65 THR A 81 LEU A 136 ALA A 146 ASP A 147	ACP A1264 (-4.7A) ACP A1264 (-2.9A) None None None ACP A1264 (-4.5A) ACP A1264 ( 4.8A) None None	1.07A	6hd4A-4ueuA: 32.2	6hd4A-4ueuA: 30.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	9	VAL A 22 ALA A 35 GLU A 52 VAL A 65 ILE A 79 THR A 81 LEU A 136 ALA A 146 ASP A 147	ACP A1264 (-4.7A) ACP A1264 (-2.9A) None None None ACP A1264 (-4.5A) ACP A1264 ( 4.8A) None None	0.88A	6hd4A-4ueuA: 32.2	6hd4A-4ueuA: 30.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	8	VAL A 22 ALA A 35 ILE A 55 ILE A 79 THR A 81 LEU A 136 ALA A 146 ASP A 147	ACP A1264 (-4.7A) ACP A1264 (-2.9A) None None ACP A1264 (-4.5A) ACP A1264 ( 4.8A) None None	1.17A	6hd4A-4ueuA: 32.2	6hd4A-4ueuA: 30.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	9	VAL A 22 ALA A 35 LYS A 37 GLU A 52 MET A 56 VAL A 65 THR A 81 ALA A 146 ASP A 147	ACP A1264 (-4.7A) ACP A1264 (-2.9A) None None None None ACP A1264 (-4.5A) None None	1.04A	6hd4A-4ueuA: 32.2	6hd4A-4ueuA: 30.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	9	VAL A 22 ALA A 35 LYS A 37 GLU A 52 VAL A 65 ILE A 79 THR A 81 ALA A 146 ASP A 147	ACP A1264 (-4.7A) ACP A1264 (-2.9A) None None None None ACP A1264 (-4.5A) None None	0.86A	6hd4A-4ueuA: 32.2	6hd4A-4ueuA: 30.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 72 GLU A 90 MET A 94 VAL A 104 ILE A 124 LEU A 183 ASP A 194	KSA A 405 (-3.2A) None None None None KSA A 405 (-4.6A) ZN A 403 ( 2.6A)	1.02A	6hd4A-4wsqA: 22.1	6hd4A-4wsqA: 14.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 60 ALA A 72 LYS A 74 GLU A 90 MET A 94 VAL A 104 ILE A 124 LEU A 183	KSA A 405 ( 4.9A) KSA A 405 (-3.2A) None None None None None KSA A 405 (-4.6A)	0.78A	6hd4A-4wsqA: 22.1	6hd4A-4wsqA: 14.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xcu	FIBROBLAST GROWTH FACTOR RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 481 ALA A 501 LYS A 503 GLU A 520 MET A 524 ILE A 527 LEU A 619 ALA A 629	40M A1002 ( 4.5A) 40M A1002 ( 4.1A) 40M A1002 (-4.0A) 40M A1002 (-3.7A) 40M A1002 (-3.8A) None 40M A1002 (-4.5A) 40M A1002 (-3.0A)	0.78A	6hd4A-4xcuA: 30.9	6hd4A-4xcuA: 18.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	8	VAL B 275 ALA B 288 LYS B 290 MET B 309 ILE B 312 VAL B 318 ILE B 332 THR B 334	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A)	0.67A	6hd4A-4xeyB: 27.9	6hd4A-4xeyB: 40.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	9	VAL B 275 ALA B 288 MET B 309 ILE B 312 VAL B 318 ILE B 332 THR B 334 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.75A	6hd4A-4xeyB: 27.9	6hd4A-4xeyB: 40.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 624 ALA A 642 LYS A 644 GLU A 661 VAL A 675 LEU A 818 ASP A 829	P30 A1001 ( 4.8A) P30 A1001 (-3.5A) P30 A1001 ( 4.0A) P30 A1001 (-3.1A) None P30 A1001 (-4.3A) None	0.62A	6hd4A-4xufA: 27.6	6hd4A-4xufA: 12.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 477 ALA A 488 LYS A 490 GLU A 509 ILE A 537 THR A 539 LEU A 595 ALA A 605	None 4CV A 801 (-3.5A) 4CV A 801 (-3.9A) None None 4CV A 801 (-2.8A) 4CV A 801 (-4.4A) 4CV A 801 ( 3.9A)	0.72A	6hd4A-4yffA: 19.0	6hd4A-4yffA: 14.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 492 ALA A 512 GLU A 531 MET A 535 ILE A 538 LEU A 630 ALA A 640	38O A1769 (-4.5A) 38O A1769 (-3.6A) EDO A1766 (-4.1A) EDO A1766 (-3.5A) None 38O A1769 (-4.6A) EDO A1766 ( 4.4A)	0.72A	6hd4A-5a46A: 30.4	6hd4A-5a46A: 12.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5es1	MAP/MICROTUBULE AFFINITY-REGULATING KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	7	VAL A 70 ALA A 83 LYS A 85 GLU A 103 VAL A 116 LEU A 185 ALA A 195	5RC A4000 (-4.6A) 5RC A4000 (-3.6A) 5RC A4000 (-2.8A) None None None 5RC A4000 ( 3.9A)	1.07A	6hd4A-5es1A: 17.0	6hd4A-5es1A: 14.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 607 ALA A 625 GLU A 644 MET A 648 VAL A 658 ILE A 672 THR A 674 LEU A 825 ASP A 836	748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 (-3.3A) 748 A1001 (-3.4A) 748 A1001 ( 4.8A) 748 A1001 (-3.9A) 748 A1001 (-3.2A) 748 A1001 (-4.3A) 748 A1001 (-4.8A)	0.62A	6hd4A-5grnA: 28.3	6hd4A-5grnA: 14.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 607 ALA A 625 LYS A 627 GLU A 644 MET A 648 ILE A 672 THR A 674 ASP A 836	748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 (-4.0A) 748 A1001 (-3.3A) 748 A1001 (-3.4A) 748 A1001 (-3.9A) 748 A1001 (-3.2A) 748 A1001 (-4.8A)	0.78A	6hd4A-5grnA: 28.3	6hd4A-5grnA: 14.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5gz8	PROTEIN O-MANNOSE KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 94 ALA A 105 VAL A 134 ILE A 146 THR A 148 LEU A 215 ASP A 226	None	0.88A	6hd4A-5gz8A: 19.0	6hd4A-5gz8A: 14.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 65 ALA A 77 LYS A 79 GLU A 95 MET A 99 VAL A 109 ILE A 128 LEU A 187	IDV A 401 (-4.6A) IDV A 401 (-3.6A) IDV A 401 ( 4.8A) None None None None IDV A 401 (-4.4A)	0.74A	6hd4A-5i3oA: 21.9	6hd4A-5i3oA: 19.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	9	VAL A 30 ALA A 43 LYS A 45 GLU A 61 MET A 65 VAL A 74 ILE A 88 LEU A 143 ALA A 153	6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) 6G2 A 901 ( 3.9A) None None None None 6G2 A 901 (-4.7A) 6G2 A 901 ( 4.2A)	0.72A	6hd4A-5j5tA: 20.8	6hd4A-5j5tA: 12.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5l6o	EPHRIN TYPE-B RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 647 ALA A 663 LYS A 665 ILE A 709 THR A 711 LEU A 765 ASP A 776	None 6P6 A1001 (-3.3A) None 6P6 A1001 ( 4.5A) 6P6 A1001 (-3.5A) 6P6 A1001 (-4.5A) None	0.63A	6hd4A-5l6oA: 33.3	6hd4A-5l6oA: 12.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5l6o	EPHRIN TYPE-B RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 647 ALA A 663 LYS A 665 MET A 686 ILE A 709 THR A 711 ASP A 776	None 6P6 A1001 (-3.3A) None 6P6 A1001 ( 4.2A) 6P6 A1001 ( 4.5A) 6P6 A1001 (-3.5A) None	0.67A	6hd4A-5l6oA: 33.3	6hd4A-5l6oA: 12.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5myv	SRSF PROTEIN KINASE 2,SRSF PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 106 ALA A 119 LYS A 121 GLU A 136 VAL A 157 LEU A 232 ALA A 540	W4A A 716 ( 4.7A) W4A A 716 ( 3.9A) SO4 A 702 (-3.3A) DMS A 717 (-4.0A) DMS A 717 (-4.3A) None DMS A 717 ( 4.5A)	0.99A	6hd4A-5myvA: 19.7	6hd4A-5myvA: 11.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	6	VAL A 899 ALA A 917 LYS A 919 ILE A 961 THR A 963 LEU A1017	ANP A1201 (-4.4A) ANP A1201 (-3.3A) ANP A1201 (-3.8A) None ANP A1201 (-3.9A) ANP A1201 (-4.7A)	0.61A	6hd4A-5wnoA: 27.8	6hd4A-5wnoA: 28.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6b3e	CYCLIN-DEPENDENT KINASE 12 (Homo sapiens)	no annotation	6	VAL A 741 ALA A 754 GLU A 774 VAL A 787 LEU A 866 ALA A 876	None CJM A1102 (-3.1A) None None CJM A1102 (-4.4A) CJM A1102 (-3.6A)	0.56A	6hd4A-6b3eA: 22.6	6hd4A-6b3eA: 32.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c9d	SERINE/THREONINE-PRO TEIN KINASE MARK1,SERINE/THREONI NE-PROTEIN KINASE MARK1 (Homo sapiens)	no annotation	8	VAL A 74 ALA A 87 LYS A 89 GLU A 107 MET A 111 VAL A 120 LEU A 189 ALA A 199	None	0.99A	6hd4A-6c9dA: 21.0	6hd4A-6c9dA: 24.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cmj	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	7	VAL A 179 ALA A 192 LYS A 194 GLU A 236 VAL A 249 LEU A 319 ALA A 329	F6J A 501 (-4.6A) F6J A 501 (-3.4A) F6J A 501 (-2.9A) F6J A 501 ( 4.7A) None F6J A 501 (-4.5A) F6J A 501 ( 4.0A)	0.89A	6hd4A-6cmjA: 22.0	6hd4A-6cmjA: 19.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fyl	DUAL SPECIFICITY PROTEIN KINASE CLK2 (Homo sapiens)	no annotation	7	VAL A 177 ALA A 191 GLU A 208 ILE A 215 ILE A 241 LEU A 297 ASP A 327	3NG A 501 ( 4.4A) 3NG A 501 (-3.3A) 3NG A 501 ( 4.9A) None None None 3NG A 501 (-4.5A)	1.20A	6hd4A-6fylA: 7.3	6hd4A-6fylA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fyl	DUAL SPECIFICITY PROTEIN KINASE CLK2 (Homo sapiens)	no annotation	7	VAL A 177 ALA A 191 GLU A 208 VAL A 227 ILE A 241 LEU A 297 ASP A 327	3NG A 501 ( 4.4A) 3NG A 501 (-3.3A) 3NG A 501 ( 4.9A) None None None 3NG A 501 (-4.5A)	1.03A	6hd4A-6fylA: 7.3	6hd4A-6fylA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fyl	DUAL SPECIFICITY PROTEIN KINASE CLK2 (Homo sapiens)	no annotation	7	VAL A 177 ALA A 191 LYS A 193 GLU A 208 ILE A 215 ILE A 241 LEU A 297	3NG A 501 ( 4.4A) 3NG A 501 (-3.3A) 3NG A 501 (-3.0A) 3NG A 501 ( 4.9A) None None None	1.01A	6hd4A-6fylA: 7.3	6hd4A-6fylA: undetectable

[["6HD4_A_STIA604_0","1gng","Homo sapiens","GLYCOGEN SYNTHASE KINASE-3 BETA","PF00069(Pkinase)",6,"VAL A  70;ALA A  83;LYS A  85;GLU A  97;VAL A 110;LEU A 188","None","0.59A","6hd4A-1gngA:20.4","6hd4A-1gngA:12.42"],["6HD4_A_STIA604_0","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"VAL A 209;ALA A 220;GLU A 236;MET A 240;VAL A 249;ILE A 264;THR A 266;LEU A 321","None","0.70A","6hd4A-1k9aA:26.8","6hd4A-1k9aA:16.47"],["6HD4_A_STIA604_0","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"VAL A 209;ALA A 220;LYS A 222;GLU A 236;MET A 240;VAL A 249;ILE A 264;THR A 266","None","0.59A","6hd4A-1k9aA:26.8","6hd4A-1k9aA:16.47"],["6HD4_A_STIA604_0","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",7,"ALA A 606;LYS A 608;MET A 629;VAL A 638;LEU A 731;ALA A 741;ASP A 742","None","1.16A","6hd4A-1lufA:34.0","6hd4A-1lufA:31.03"],["6HD4_A_STIA604_0","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",7,"VAL A 588;ALA A 606;LYS A 608;VAL A 638;LEU A 731;ALA A 741;ASP A 742","None","0.86A","6hd4A-1lufA:34.0","6hd4A-1lufA:31.03"],["6HD4_A_STIA604_0","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",11,"VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;ILE A 312;VAL A 318;ILE A 332;THR A 334;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.70A","6hd4A-1opkA:36.8","6hd4A-1opkA:28.37"],["6HD4_A_STIA604_0","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",7,"VAL A 603;ALA A 621;GLU A 640;VAL A 654;THR A 670;LEU A 799;ASP A 810","STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-3.6A);STI A   3 (-4.3A);STI A   3 (-3.2A);STI A   3 (-4.4A);STI A   3 (-3.9A)","0.54A","6hd4A-1t46A:33.7","6hd4A-1t46A:14.24"],["6HD4_A_STIA604_0","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",7,"VAL A 352;ALA A 367;LYS A 369;GLU A 386;MET A 390;VAL A 399;LEU A 468","STU A 100 (-4.8A);STU A 100 (-3.2A);STU A 100 ( 4.7A);None;None;None;STU A 100 (-4.5A)","0.60A","6hd4A-1u59A:29.8","6hd4A-1u59A:15.23"],["6HD4_A_STIA604_0","1zrz","Homo sapiens","PROTEIN KINASE C, IOTA","PF00069(Pkinase);PF00433(Pkinase_C)",7,"VAL A 259;ALA A 272;LYS A 274;GLU A 293;VAL A 307;LEU A 376;ASP A 387","BI1 A1000 (-4.2A);BI1 A1000 (-3.4A);BI1 A1000 (-3.5A);BI1 A1000 ( 4.9A);BI1 A1000 (-4.4A);BI1 A1000 (-4.8A);BI1 A1000 (-4.5A)","1.06A","6hd4A-1zrzA:20.0","6hd4A-1zrzA:14.04"],["6HD4_A_STIA604_0","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",7,"GLU X  54;MET X  58;VAL X  67;ILE X  80;THR X  82;ALA X 147;ASP X 148","STU X 902 ( 4.4A);None;None;None;STU X 902 (-4.1A);STU X 902 ( 4.1A);STU X 902 (-3.6A)","0.99A","6hd4A-2dq7X:31.5","6hd4A-2dq7X:17.96"],["6HD4_A_STIA604_0","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",10,"VAL X  25;ALA X  37;LYS X  39;GLU X  54;MET X  58;VAL X  67;ILE X  80;THR X  82;LEU X 137;ALA X 147","STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-3.1A);STU X 902 ( 4.4A);None;None;None;STU X 902 (-4.1A);STU X 902 (-4.4A);STU X 902 ( 4.1A)","0.73A","6hd4A-2dq7X:31.5","6hd4A-2dq7X:17.96"],["6HD4_A_STIA604_0","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",8,"VAL A 170;ALA A 184;GLU A 201;ILE A 208;VAL A 220;ILE A 234;LEU A 290;ALA A 319","None","0.72A","6hd4A-2eu9A:21.1","6hd4A-2eu9A:13.33"],["6HD4_A_STIA604_0","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",8,"VAL A 170;ALA A 184;LYS A 186;GLU A 201;ILE A 208;ILE A 234;LEU A 290;ALA A 319","None","0.79A","6hd4A-2eu9A:21.1","6hd4A-2eu9A:13.33"],["6HD4_A_STIA604_0","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"VAL A 281;ALA A 293;LYS A 295;VAL A 323;ILE A 336;THR A 338","H8H A 534 (-4.4A);H8H A 534 (-3.2A);H8H A 534 (-3.7A);None;H8H A 534 ( 4.5A);H8H A 534 (-3.1A)","0.58A","6hd4A-2h8hA:29.7","6hd4A-2h8hA:9.51"],["6HD4_A_STIA604_0","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"VAL A 281;ALA A 293;VAL A 323;ILE A 336;THR A 338;LEU A 393;ALA A 403","H8H A 534 (-4.4A);H8H A 534 (-3.2A);None;H8H A 534 ( 4.5A);H8H A 534 (-3.1A);H8H A 534 (-4.5A);H8H A 534 ( 4.0A)","0.92A","6hd4A-2h8hA:29.7","6hd4A-2h8hA:9.51"],["6HD4_A_STIA604_0","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"VAL A 281;ALA A 293;LYS A 295;VAL A 323;ILE A 336;THR A 338;ALA A 403","QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;None;None;QUE A   1 (-3.3A);QUE A   1 ( 4.5A)","0.95A","6hd4A-2hckA:29.2","6hd4A-2hckA:13.06"],["6HD4_A_STIA604_0","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"VAL A 281;ALA A 293;VAL A 323;ILE A 336;THR A 338;LEU A 393;ALA A 403","QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;None;QUE A   1 (-3.3A);QUE A   1 (-4.4A);QUE A   1 ( 4.5A)","0.95A","6hd4A-2hckA:29.2","6hd4A-2hckA:13.06"],["6HD4_A_STIA604_0","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",10,"VAL A 259;ALA A 271;GLU A 288;MET A 292;VAL A 301;ILE A 314;THR A 316;LEU A 371;ALA A 381;ASP A 382","1BM A 499 ( 4.8A);1BM A 499 (-3.6A);1BM A 499 (-3.2A);1BM A 499 ( 3.8A);None;1BM A 499 (-3.9A);1BM A 499 (-3.2A);1BM A 499 (-4.4A);1BM A 499 ( 3.7A);1BM A 499 (-4.4A)","1.01A","6hd4A-2hk5A:26.5","6hd4A-2hk5A:18.05"],["6HD4_A_STIA604_0","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",8,"VAL A 259;ALA A 271;LYS A 273;GLU A 288;MET A 292;VAL A 301;ILE A 314;THR A 316","1BM A 499 ( 4.8A);1BM A 499 (-3.6A);1BM A 499 (-3.8A);1BM A 499 (-3.2A);1BM A 499 ( 3.8A);None;1BM A 499 (-3.9A);1BM A 499 (-3.2A)","0.62A","6hd4A-2hk5A:26.5","6hd4A-2hk5A:18.05"],["6HD4_A_STIA604_0","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",10,"ALA A 269;GLU A 286;MET A 290;ILE A 293;VAL A 299;ILE A 313;THR A 315;LEU A 370;ALA A 380;ASP A 381","GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.2A);GIN A 600 (-4.5A);GIN A 600 (-4.6A);GIN A 600 (-3.8A);GIN A 600 (-3.4A);GIN A 600 (-4.7A);GIN A 600 (-3.1A);GIN A 600 (-4.9A)","0.78A","6hd4A-2hz0A:34.3","6hd4A-2hz0A:92.50"],["6HD4_A_STIA604_0","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",10,"VAL A 256;ALA A 269;GLU A 286;MET A 290;ILE A 293;VAL A 299;ILE A 313;THR A 315;LEU A 370;ALA A 380","GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.2A);GIN A 600 (-4.5A);GIN A 600 (-4.6A);GIN A 600 (-3.8A);GIN A 600 (-3.4A);GIN A 600 (-4.7A);GIN A 600 (-3.1A)","0.59A","6hd4A-2hz0A:34.3","6hd4A-2hz0A:92.50"],["6HD4_A_STIA604_0","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",7,"VAL A 256;ALA A 269;LYS A 271;GLU A 286;MET A 290;ILE A 293;ILE A 313","GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.6A);GIN A 600 (-3.2A);GIN A 600 (-4.5A);GIN A 600 (-3.8A)","0.78A","6hd4A-2hz0A:34.3","6hd4A-2hz0A:92.50"],["6HD4_A_STIA604_0","2j0j","Gallus gallus","FOCAL ADHESION KINASE 1","PF00373(FERM_M);PF07714(Pkinase_Tyr)",7,"ALA A 452;LYS A 454;GLU A 471;MET A 475;VAL A 484;ILE A 497;ASP A 564","4ST A1687 (-3.3A);4ST A1687 (-3.4A);4ST A1687 ( 4.6A);None;None;None;4ST A1687 (-4.7A)","0.83A","6hd4A-2j0jA:31.7","6hd4A-2j0jA:7.69"],["6HD4_A_STIA604_0","2j0j","Gallus gallus","FOCAL ADHESION KINASE 1","PF00373(FERM_M);PF07714(Pkinase_Tyr)",8,"VAL A 436;ALA A 452;LYS A 454;GLU A 471;MET A 475;VAL A 484;ILE A 497;LEU A 553","4ST A1687 ( 4.8A);4ST A1687 (-3.3A);4ST A1687 (-3.4A);4ST A1687 ( 4.6A);None;None;None;4ST A1687 (-4.4A)","0.70A","6hd4A-2j0jA:31.7","6hd4A-2j0jA:7.69"],["6HD4_A_STIA604_0","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",10,"VAL A 259;ALA A 271;GLU A 288;MET A 292;VAL A 301;ILE A 314;THR A 316;LEU A 371;ALA A 381;ASP A 382","None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.6A);1N8 A 501 ( 3.6A);None;1N8 A 501 ( 4.6A);1N8 A 501 ( 3.3A);1N8 A 501 ( 4.3A);1N8 A 501 ( 3.3A);1N8 A 501 ( 3.3A)","0.57A","6hd4A-2og8A:26.1","6hd4A-2og8A:16.50"],["6HD4_A_STIA604_0","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",8,"VAL A 259;ALA A 271;LYS A 273;GLU A 288;MET A 292;ILE A 314;ALA A 381;ASP A 382","None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.4A);1N8 A 501 ( 3.6A);1N8 A 501 ( 3.6A);1N8 A 501 ( 4.6A);1N8 A 501 ( 3.3A);1N8 A 501 ( 3.3A)","0.79A","6hd4A-2og8A:26.1","6hd4A-2og8A:16.50"],["6HD4_A_STIA604_0","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",7,"VAL A 596;ALA A 614;GLU A 633;MET A 637;VAL A 647;THR A 663;ASP A 796","None","0.93A","6hd4A-2ogvA:22.1","6hd4A-2ogvA:14.97"],["6HD4_A_STIA604_0","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",7,"VAL A 596;ALA A 614;GLU A 633;MET A 637;VAL A 647;THR A 663;LEU A 785","None","0.86A","6hd4A-2ogvA:22.1","6hd4A-2ogvA:14.97"],["6HD4_A_STIA604_0","2p4i","Homo sapiens","ANGIOPOIETIN-1 RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 838;ALA A 853;LYS A 855;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 4.6A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.58A","6hd4A-2p4iA:12.2","6hd4A-2p4iA:12.80"],["6HD4_A_STIA604_0","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 495;ALA A 515;GLU A 534;MET A 538;ILE A 541;LEU A 633;ALA A 643","None","0.63A","6hd4A-2psqA:31.4","6hd4A-2psqA:14.25"],["6HD4_A_STIA604_0","2qob","Homo sapiens","EPHRIN RECEPTOR","PF07714(Pkinase_Tyr)",7,"VAL A 635;ALA A 651;GLU A 670;MET A 674;ILE A 697;THR A 699;ASP A 764","BME A   1 (-4.9A);PTR A 701 ( 4.7A);None;None;None;None;None","1.04A","6hd4A-2qobA:26.1","6hd4A-2qobA:13.16"],["6HD4_A_STIA604_0","2vd5","Homo sapiens","DMPK PROTEIN","PF00069(Pkinase)",6,"VAL A  85;ALA A  98;LYS A 100;GLU A 119;LEU A 202;ALA A 212","BI8 A1417 ( 4.7A);BI8 A1417 ( 3.8A);BI8 A1417 (-4.2A);BI8 A1417 ( 4.9A);BI8 A1417 (-4.8A);BI8 A1417 ( 4.1A)","0.59A","6hd4A-2vd5A:19.3","6hd4A-2vd5A:10.24"],["6HD4_A_STIA604_0","2xik","Homo sapiens","SERINE\/THREONINE PROTEIN KINASE 25","PF00069(Pkinase)",7,"VAL A  34;ALA A  47;LYS A  49;GLU A  66;ILE A  93;LEU A 147;ALA A 157","J60 A1294 ( 4.9A);J60 A1294 (-3.3A);None;None;None;J60 A1294 (-4.8A);J60 A1294 ( 4.2A)","0.82A","6hd4A-2xikA:18.3","6hd4A-2xikA:15.05"],["6HD4_A_STIA604_0","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",8,"VAL A 635;ALA A 651;LYS A 653;MET A 674;ILE A 697;THR A 699;LEU A 753;ASP A 764","Q9G A1898 ( 4.7A);Q9G A1898 (-3.2A);Q9G A1898 (-4.8A);Q9G A1898 (-3.9A);Q9G A1898 ( 4.6A);Q9G A1898 (-3.5A);Q9G A1898 (-4.3A);None","0.77A","6hd4A-2xyuA:32.4","6hd4A-2xyuA:14.79"],["6HD4_A_STIA604_0","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"VAL A 261;ALA A 273;GLU A 290;MET A 294;VAL A 303;THR A 319;ASP A 385","None","1.06A","6hd4A-2zv7A:30.8","6hd4A-2zv7A:19.81"],["6HD4_A_STIA604_0","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"VAL A 261;ALA A 273;GLU A 290;VAL A 303;ILE A 317;THR A 319;ASP A 385","None","0.87A","6hd4A-2zv7A:30.8","6hd4A-2zv7A:19.81"],["6HD4_A_STIA604_0","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"VAL A 261;ALA A 273;MET A 294;VAL A 303;THR A 319;ALA A 384;ASP A 385","None","1.08A","6hd4A-2zv7A:30.8","6hd4A-2zv7A:19.81"],["6HD4_A_STIA604_0","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"VAL A 261;ALA A 273;MET A 294;VAL A 303;THR A 319;LEU A 374;ALA A 384","None","1.11A","6hd4A-2zv7A:30.8","6hd4A-2zv7A:19.81"],["6HD4_A_STIA604_0","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"VAL A 261;ALA A 273;VAL A 303;ILE A 317;THR A 319;ALA A 384;ASP A 385","None","0.70A","6hd4A-2zv7A:30.8","6hd4A-2zv7A:19.81"],["6HD4_A_STIA604_0","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"VAL A 261;ALA A 273;VAL A 303;ILE A 317;THR A 319;LEU A 374;ALA A 384","None","0.86A","6hd4A-2zv7A:30.8","6hd4A-2zv7A:19.81"],["6HD4_A_STIA604_0","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"VAL A 492;ALA A 512;GLU A 531;MET A 535;ILE A 538;LEU A 630;ALA A 640","None;C4F A   1 (-3.3A);None;C4F A   1 ( 3.7A);None;C4F A   1 (-4.6A);C4F A   1 (-3.6A)","0.68A","6hd4A-3c4fA:24.7","6hd4A-3c4fA:14.53"],["6HD4_A_STIA604_0","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",8,"VAL A 209;ALA A 220;GLU A 236;MET A 240;VAL A 249;ILE A 264;THR A 266;LEU A 321","None","0.70A","6hd4A-3d7uA:26.8","6hd4A-3d7uA:15.53"],["6HD4_A_STIA604_0","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",8,"VAL A 209;ALA A 220;LYS A 222;GLU A 236;MET A 240;VAL A 249;ILE A 264;THR A 266","None","0.59A","6hd4A-3d7uA:26.8","6hd4A-3d7uA:15.53"],["6HD4_A_STIA604_0","3dko","Homo sapiens","EPHRIN TYPE-A RECEPTOR 7","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",8,"VAL A 647;ALA A 663;LYS A 665;GLU A 682;MET A 686;VAL A 695;ILE A 709;ASP A 776","IHZ A1001 ( 4.4A);IHZ A1001 (-3.3A);IHZ A1001 ( 4.5A);IHZ A1001 (-3.8A);IHZ A1001 (-3.5A);IHZ A1001 ( 4.9A);None;IHZ A1001 (-4.8A)","0.73A","6hd4A-3dkoA:30.4","6hd4A-3dkoA:13.26"],["6HD4_A_STIA604_0","3dko","Homo sapiens","EPHRIN TYPE-A RECEPTOR 7","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 647;ALA A 663;LYS A 665;VAL A 695;ILE A 709;LEU A 765;ASP A 776","IHZ A1001 ( 4.4A);IHZ A1001 (-3.3A);IHZ A1001 ( 4.5A);IHZ A1001 ( 4.9A);None;IHZ A1001 (-4.6A);IHZ A1001 (-4.8A)","0.70A","6hd4A-3dkoA:30.4","6hd4A-3dkoA:13.26"],["6HD4_A_STIA604_0","3fme","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","PF00069(Pkinase)",6,"VAL A  67;ALA A  80;LYS A  82;VAL A 113;ILE A 127;LEU A 186","None;STU A   1 (-3.4A);STU A   1 ( 4.2A);None;None;STU A   1 (-4.4A)","0.60A","6hd4A-3fmeA:16.9","6hd4A-3fmeA:16.91"],["6HD4_A_STIA604_0","3gp0","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 11","PF00069(Pkinase)",6,"VAL A  38;ALA A  51;LYS A  53;GLU A  71;THR A 106;ASP A 168","NIL A   1 ( 4.7A);NIL A   1 (-3.7A);None;NIL A   1 (-3.7A);NIL A   1 (-3.3A);NIL A   1 (-4.6A)","0.53A","6hd4A-3gp0A:21.9","6hd4A-3gp0A:13.26"],["6HD4_A_STIA604_0","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"VAL A 841;ALA A 859;GLU A 878;ILE A 885;VAL A 892;LEU A1029;ASP A1040","8ST A2001 ( 4.6A);8ST A2001 ( 3.8A);8ST A2001 (-3.7A);None;8ST A2001 ( 4.7A);None;None","0.87A","6hd4A-3hngA:32.7","6hd4A-3hngA:12.22"],["6HD4_A_STIA604_0","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"VAL A 841;ALA A 859;LYS A 861;GLU A 878;ILE A 885;VAL A 892;ASP A1040","8ST A2001 ( 4.6A);8ST A2001 ( 3.8A);8ST A2001 (-4.0A);8ST A2001 (-3.7A);None;8ST A2001 ( 4.7A);None","0.91A","6hd4A-3hngA:32.7","6hd4A-3hngA:12.22"],["6HD4_A_STIA604_0","3iec","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK2","PF00069(Pkinase);PF00627(UBA)",7,"VAL A  67;ALA A  80;LYS A  82;MET A 104;VAL A 113;ALA A 192;ASP A 193","None","0.68A","6hd4A-3iecA:22.3","6hd4A-3iecA:13.61"],["6HD4_A_STIA604_0","3iec","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK2","PF00069(Pkinase);PF00627(UBA)",7,"VAL A  67;ALA A  80;LYS A  82;MET A 104;VAL A 113;LEU A 182;ALA A 192","None","0.73A","6hd4A-3iecA:22.3","6hd4A-3iecA:13.61"],["6HD4_A_STIA604_0","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 649;ALA A 665;GLU A 684;MET A 688;ILE A 711;THR A 713;LEU A 767","None","0.65A","6hd4A-3kulA:31.4","6hd4A-3kulA:11.81"],["6HD4_A_STIA604_0","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 649;ALA A 665;LYS A 667;GLU A 684;MET A 688;ILE A 711;THR A 713","None","0.77A","6hd4A-3kulA:31.4","6hd4A-3kulA:11.81"],["6HD4_A_STIA604_0","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",7,"VAL A 218;ALA A 229;LYS A 231;GLU A 244;THR A 279;LEU A 339;ALA A 349","LDN A   1 ( 4.8A);LDN A   1 (-3.6A);None;None;LDN A   1 (-3.8A);LDN A   1 (-4.5A);LDN A   1 ( 3.8A)","0.77A","6hd4A-3mdyA:24.4","6hd4A-3mdyA:13.02"],["6HD4_A_STIA604_0","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",8,"ALA A 576;LYS A 578;GLU A 596;MET A 600;VAL A 609;ILE A 623;THR A 625;LEU A 683","STU A   1 (-3.3A);STU A   1 (-3.5A);None;None;None;None;STU A   1 (-4.1A);STU A   1 (-4.3A)","0.73A","6hd4A-3ppzA:28.3","6hd4A-3ppzA:12.67"],["6HD4_A_STIA604_0","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",8,"VAL A 565;ALA A 576;LYS A 578;MET A 600;VAL A 609;ILE A 623;THR A 625;LEU A 683","STU A   1 (-4.9A);STU A   1 (-3.3A);STU A   1 (-3.5A);None;None;None;STU A   1 (-4.1A);STU A   1 (-4.3A)","0.75A","6hd4A-3ppzA:28.3","6hd4A-3ppzA:12.67"],["6HD4_A_STIA604_0","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",7,"VAL A 431;ALA A 443;MET A 464;VAL A 473;ILE A 487;THR A 489;LEU A 543","PP2 A   1 (-4.5A);PP2 A   1 (-3.2A);PP2 A   1 ( 4.3A);None;PP2 A   1 (-3.6A);PP2 A   1 (-3.3A);PP2 A   1 (-4.6A)","0.68A","6hd4A-3sxsA:25.0","6hd4A-3sxsA:12.73"],["6HD4_A_STIA604_0","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"VAL A 492;ALA A 512;LYS A 514;GLU A 531;MET A 535;ILE A 538;LEU A 630;ALA A 640","07J A   1 (-4.0A);07J A   1 (-3.5A);07J A   1 (-4.5A);07J A   1 (-3.8A);07J A   1 (-3.8A);None;07J A   1 ( 4.4A);07J A   1 (-3.2A)","0.69A","6hd4A-3tt0A:30.4","6hd4A-3tt0A:13.58"],["6HD4_A_STIA604_0","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"VAL A 848;ALA A 866;LYS A 868;GLU A 885;ILE A 892;VAL A 899;LEU A1035;ASP A1046","4TT A2001 ( 4.5A);4TT A2001 (-3.5A);None;None;None;None;4TT A2001 (-4.8A);None","0.77A","6hd4A-3vidA:29.9","6hd4A-3vidA:14.84"],["6HD4_A_STIA604_0","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 848;ALA A 866;LYS A 868;GLU A 885;ILE A 892;VAL A 899;LEU A1035","LEV A1201 ( 4.9A);LEV A1201 (-3.5A);None;LEV A1201 (-3.7A);None;None;LEV A1201 (-4.8A)","0.61A","6hd4A-3wzdA:30.7","6hd4A-3wzdA:14.90"],["6HD4_A_STIA604_0","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 848;ALA A 866;GLU A 885;ILE A 892;VAL A 899;LEU A1035;ASP A1046","None;B49 A2000 (-3.5A);None;None;B49 A2000 ( 4.6A);B49 A2000 (-4.5A);None","0.80A","6hd4A-4agdA:32.5","6hd4A-4agdA:14.49"],["6HD4_A_STIA604_0","4bc6","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 10","PF00069(Pkinase)",7,"VAL A  50;ALA A  63;GLU A  81;VAL A  94;ILE A 108;LEU A 164;ALA A 174","XZN A1317 ( 4.7A);XZN A1317 (-3.5A);XZN A1317 (-3.9A);XZN A1317 (-4.4A);XZN A1317 (-4.4A);XZN A1317 (-4.7A);XZN A1317 ( 4.3A)","0.70A","6hd4A-4bc6A:21.2","6hd4A-4bc6A:16.45"],["6HD4_A_STIA604_0","4bc6","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 10","PF00069(Pkinase)",7,"VAL A  50;ALA A  63;LYS A  65;ILE A  84;ILE A 108;LEU A 164;ALA A 174","XZN A1317 ( 4.7A);XZN A1317 (-3.5A);XZN A1317 (-4.1A);None;XZN A1317 (-4.4A);XZN A1317 (-4.7A);XZN A1317 ( 4.3A)","1.11A","6hd4A-4bc6A:21.2","6hd4A-4bc6A:16.45"],["6HD4_A_STIA604_0","4bc6","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 10","PF00069(Pkinase)",7,"VAL A  50;ALA A  63;LYS A  65;VAL A  94;ILE A 108;LEU A 164;ALA A 174","XZN A1317 ( 4.7A);XZN A1317 (-3.5A);XZN A1317 (-4.1A);XZN A1317 (-4.4A);XZN A1317 (-4.4A);XZN A1317 (-4.7A);XZN A1317 ( 4.3A)","0.78A","6hd4A-4bc6A:21.2","6hd4A-4bc6A:16.45"],["6HD4_A_STIA604_0","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",9,"VAL A 624;ALA A 653;LYS A 655;GLU A 672;MET A 676;THR A 701;LEU A 773;ALA A 783;ASP A 784","DI1 A1000 (-4.8A);DI1 A1000 (-3.6A);DI1 A1000 (-3.9A);DI1 A1000 (-3.8A);DI1 A1000 (-3.6A);DI1 A1000 (-3.6A);DI1 A1000 (-4.5A);DI1 A1000 (-3.7A);DI1 A1000 (-4.1A)","0.70A","6hd4A-4ckrA:32.1","6hd4A-4ckrA:13.45"],["6HD4_A_STIA604_0","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",7,"VAL A 836;ALA A 853;LYS A 855;GLU A 871;VAL A 884;LEU A 956;ALA A 966","19S A1201 (-4.4A);19S A1201 (-3.3A);19S A1201 (-3.5A);None;None;19S A1201 (-4.5A);19S A1201 ( 4.1A)","0.66A","6hd4A-4hviA:29.0","6hd4A-4hviA:12.70"],["6HD4_A_STIA604_0","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",7,"VAL A 486;ALA A 506;GLU A 525;MET A 529;ILE A 532;LEU A 624;ALA A 634","ACP A 801 (-4.2A);ACP A 801 (-3.3A);ACP A 801 ( 4.8A);None;None;ACP A 801 (-4.4A);None","0.81A","6hd4A-4k33A:30.8","6hd4A-4k33A:15.34"],["6HD4_A_STIA604_0","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",6,"VAL A 486;ALA A 506;LYS A 508;GLU A 525;MET A 529;ILE A 532","ACP A 801 (-4.2A);ACP A 801 (-3.3A);ACP A 801 (-2.7A);ACP A 801 ( 4.8A);None;None","0.50A","6hd4A-4k33A:30.8","6hd4A-4k33A:15.34"],["6HD4_A_STIA604_0","4lg4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",7,"VAL A  41;ALA A  54;GLU A  70;MET A  74;VAL A  83;LEU A 153;ALA A 163","GOL A 404 (-4.5A);GOL A 404 ( 3.1A);None;None;GOL A 403 (-4.1A);GOL A 403 ( 4.4A);GOL A 403 ( 3.0A)","1.13A","6hd4A-4lg4A:17.0","6hd4A-4lg4A:15.41"],["6HD4_A_STIA604_0","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",7,"VAL A  54;ALA A  67;GLU A  85;MET A  89;VAL A  99;THR A 123;LEU A 180","None;SIN A 401 ( 3.7A);None;None;None;None;SIN A 401 ( 4.5A)","0.85A","6hd4A-4o38A:19.1","6hd4A-4o38A:14.42"],["6HD4_A_STIA604_0","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",7,"VAL A  54;ALA A  67;LYS A  69;GLU A  85;MET A  89;VAL A  99;THR A 123","None;SIN A 401 ( 3.7A);None;None;None;None;None","0.78A","6hd4A-4o38A:19.1","6hd4A-4o38A:14.42"],["6HD4_A_STIA604_0","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",9,"VAL A  22;ALA A  35;GLU A  52;MET A  56;VAL A  65;THR A  81;LEU A 136;ALA A 146;ASP A 147","ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;None;None;ACP A1264 (-4.5A);ACP A1264 ( 4.8A);None;None","1.07A","6hd4A-4ueuA:32.2","6hd4A-4ueuA:30.86"],["6HD4_A_STIA604_0","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",9,"VAL A  22;ALA A  35;GLU A  52;VAL A  65;ILE A  79;THR A  81;LEU A 136;ALA A 146;ASP A 147","ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;None;None;ACP A1264 (-4.5A);ACP A1264 ( 4.8A);None;None","0.88A","6hd4A-4ueuA:32.2","6hd4A-4ueuA:30.86"],["6HD4_A_STIA604_0","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",8,"VAL A  22;ALA A  35;ILE A  55;ILE A  79;THR A  81;LEU A 136;ALA A 146;ASP A 147","ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;None;ACP A1264 (-4.5A);ACP A1264 ( 4.8A);None;None","1.17A","6hd4A-4ueuA:32.2","6hd4A-4ueuA:30.86"],["6HD4_A_STIA604_0","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",9,"VAL A  22;ALA A  35;LYS A  37;GLU A  52;MET A  56;VAL A  65;THR A  81;ALA A 146;ASP A 147","ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;None;None;None;ACP A1264 (-4.5A);None;None","1.04A","6hd4A-4ueuA:32.2","6hd4A-4ueuA:30.86"],["6HD4_A_STIA604_0","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",9,"VAL A  22;ALA A  35;LYS A  37;GLU A  52;VAL A  65;ILE A  79;THR A  81;ALA A 146;ASP A 147","ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;None;None;None;ACP A1264 (-4.5A);None;None","0.86A","6hd4A-4ueuA:32.2","6hd4A-4ueuA:30.86"],["6HD4_A_STIA604_0","4wsq","Homo sapiens","AP2-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"ALA A  72;GLU A  90;MET A  94;VAL A 104;ILE A 124;LEU A 183;ASP A 194","KSA A 405 (-3.2A);None;None;None;None;KSA A 405 (-4.6A); ZN A 403 ( 2.6A)","1.02A","6hd4A-4wsqA:22.1","6hd4A-4wsqA:14.33"],["6HD4_A_STIA604_0","4wsq","Homo sapiens","AP2-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",8,"VAL A  60;ALA A  72;LYS A  74;GLU A  90;MET A  94;VAL A 104;ILE A 124;LEU A 183","KSA A 405 ( 4.9A);KSA A 405 (-3.2A);None;None;None;None;None;KSA A 405 (-4.6A)","0.78A","6hd4A-4wsqA:22.1","6hd4A-4wsqA:14.33"],["6HD4_A_STIA604_0","4xcu","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 4","PF07714(Pkinase_Tyr)",8,"VAL A 481;ALA A 501;LYS A 503;GLU A 520;MET A 524;ILE A 527;LEU A 619;ALA A 629","40M A1002 ( 4.5A);40M A1002 ( 4.1A);40M A1002 (-4.0A);40M A1002 (-3.7A);40M A1002 (-3.8A);None;40M A1002 (-4.5A);40M A1002 (-3.0A)","0.78A","6hd4A-4xcuA:30.9","6hd4A-4xcuA:18.15"],["6HD4_A_STIA604_0","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",8,"VAL B 275;ALA B 288;LYS B 290;MET B 309;ILE B 312;VAL B 318;ILE B 332;THR B 334","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A)","0.67A","6hd4A-4xeyB:27.9","6hd4A-4xeyB:40.64"],["6HD4_A_STIA604_0","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",9,"VAL B 275;ALA B 288;MET B 309;ILE B 312;VAL B 318;ILE B 332;THR B 334;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.75A","6hd4A-4xeyB:27.9","6hd4A-4xeyB:40.64"],["6HD4_A_STIA604_0","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"VAL A 624;ALA A 642;LYS A 644;GLU A 661;VAL A 675;LEU A 818;ASP A 829","P30 A1001 ( 4.8A);P30 A1001 (-3.5A);P30 A1001 ( 4.0A);P30 A1001 (-3.1A);None;P30 A1001 (-4.3A);None","0.62A","6hd4A-4xufA:27.6","6hd4A-4xufA:12.87"],["6HD4_A_STIA604_0","4yff","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TNNI3K","PF07714(Pkinase_Tyr)",8,"VAL A 477;ALA A 488;LYS A 490;GLU A 509;ILE A 537;THR A 539;LEU A 595;ALA A 605","None;4CV A 801 (-3.5A);4CV A 801 (-3.9A);None;None;4CV A 801 (-2.8A);4CV A 801 (-4.4A);4CV A 801 ( 3.9A)","0.72A","6hd4A-4yffA:19.0","6hd4A-4yffA:14.10"],["6HD4_A_STIA604_0","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",7,"VAL A 492;ALA A 512;GLU A 531;MET A 535;ILE A 538;LEU A 630;ALA A 640","38O A1769 (-4.5A);38O A1769 (-3.6A);EDO A1766 (-4.1A);EDO A1766 (-3.5A);None;38O A1769 (-4.6A);EDO A1766 ( 4.4A)","0.72A","6hd4A-5a46A:30.4","6hd4A-5a46A:12.63"],["6HD4_A_STIA604_0","5es1","Homo sapiens","MAP\/MICROTUBULE AFFINITY-REGULATING KINASE 4","PF00069(Pkinase);PF00627(UBA)",7,"VAL A  70;ALA A  83;LYS A  85;GLU A 103;VAL A 116;LEU A 185;ALA A 195","5RC A4000 (-4.6A);5RC A4000 (-3.6A);5RC A4000 (-2.8A);None;None;None;5RC A4000 ( 3.9A)","1.07A","6hd4A-5es1A:17.0","6hd4A-5es1A:14.51"],["6HD4_A_STIA604_0","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",9,"VAL A 607;ALA A 625;GLU A 644;MET A 648;VAL A 658;ILE A 672;THR A 674;LEU A 825;ASP A 836","748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 (-3.3A);748 A1001 (-3.4A);748 A1001 ( 4.8A);748 A1001 (-3.9A);748 A1001 (-3.2A);748 A1001 (-4.3A);748 A1001 (-4.8A)","0.62A","6hd4A-5grnA:28.3","6hd4A-5grnA:14.16"],["6HD4_A_STIA604_0","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",8,"VAL A 607;ALA A 625;LYS A 627;GLU A 644;MET A 648;ILE A 672;THR A 674;ASP A 836","748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 (-4.0A);748 A1001 (-3.3A);748 A1001 (-3.4A);748 A1001 (-3.9A);748 A1001 (-3.2A);748 A1001 (-4.8A)","0.78A","6hd4A-5grnA:28.3","6hd4A-5grnA:14.16"],["6HD4_A_STIA604_0","5gz8","Mus musculus","PROTEIN O-MANNOSE KINASE","PF07714(Pkinase_Tyr)",7,"VAL A  94;ALA A 105;VAL A 134;ILE A 146;THR A 148;LEU A 215;ASP A 226","None","0.88A","6hd4A-5gz8A:19.0","6hd4A-5gz8A:14.43"],["6HD4_A_STIA604_0","5i3o","Homo sapiens","BMP-2-INDUCIBLE PROTEIN KINASE","PF00069(Pkinase)",8,"VAL A  65;ALA A  77;LYS A  79;GLU A  95;MET A  99;VAL A 109;ILE A 128;LEU A 187","IDV A 401 (-4.6A);IDV A 401 (-3.6A);IDV A 401 ( 4.8A);None;None;None;None;IDV A 401 (-4.4A)","0.74A","6hd4A-5i3oA:21.9","6hd4A-5i3oA:19.53"],["6HD4_A_STIA604_0","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",9,"VAL A  30;ALA A  43;LYS A  45;GLU A  61;MET A  65;VAL A  74;ILE A  88;LEU A 143;ALA A 153","6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);6G2 A 901 ( 3.9A);None;None;None;None;6G2 A 901 (-4.7A);6G2 A 901 ( 4.2A)","0.72A","6hd4A-5j5tA:20.8","6hd4A-5j5tA:12.23"],["6HD4_A_STIA604_0","5l6o","Homo sapiens","EPHRIN TYPE-B RECEPTOR 3","PF07714(Pkinase_Tyr)",7,"VAL A 647;ALA A 663;LYS A 665;ILE A 709;THR A 711;LEU A 765;ASP A 776","None;6P6 A1001 (-3.3A);None;6P6 A1001 ( 4.5A);6P6 A1001 (-3.5A);6P6 A1001 (-4.5A);None","0.63A","6hd4A-5l6oA:33.3","6hd4A-5l6oA:12.93"],["6HD4_A_STIA604_0","5l6o","Homo sapiens","EPHRIN TYPE-B RECEPTOR 3","PF07714(Pkinase_Tyr)",7,"VAL A 647;ALA A 663;LYS A 665;MET A 686;ILE A 709;THR A 711;ASP A 776","None;6P6 A1001 (-3.3A);None;6P6 A1001 ( 4.2A);6P6 A1001 ( 4.5A);6P6 A1001 (-3.5A);None","0.67A","6hd4A-5l6oA:33.3","6hd4A-5l6oA:12.93"],["6HD4_A_STIA604_0","5myv","Homo sapiens","SRSF PROTEIN KINASE 2,SRSF PROTEIN KINASE 2","PF00069(Pkinase)",7,"VAL A 106;ALA A 119;LYS A 121;GLU A 136;VAL A 157;LEU A 232;ALA A 540","W4A A 716 ( 4.7A);W4A A 716 ( 3.9A);SO4 A 702 (-3.3A);DMS A 717 (-4.0A);DMS A 717 (-4.3A);None;DMS A 717 ( 4.5A)","0.99A","6hd4A-5myvA:19.7","6hd4A-5myvA:11.60"],["6HD4_A_STIA604_0","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",6,"VAL A 899;ALA A 917;LYS A 919;ILE A 961;THR A 963;LEU A1017","ANP A1201 (-4.4A);ANP A1201 (-3.3A);ANP A1201 (-3.8A);None;ANP A1201 (-3.9A);ANP A1201 (-4.7A)","0.61A","6hd4A-5wnoA:27.8","6hd4A-5wnoA:28.89"],["6HD4_A_STIA604_0","6b3e","Homo sapiens","CYCLIN-DEPENDENT KINASE 12","no annotation",6,"VAL A 741;ALA A 754;GLU A 774;VAL A 787;LEU A 866;ALA A 876","None;CJM A1102 (-3.1A);None;None;CJM A1102 (-4.4A);CJM A1102 (-3.6A)","0.56A","6hd4A-6b3eA:22.6","6hd4A-6b3eA:32.50"],["6HD4_A_STIA604_0","6c9d","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK1,SERINE\/THREONINE-PROTEIN KINASE MARK1","no annotation",8,"VAL A  74;ALA A  87;LYS A  89;GLU A 107;MET A 111;VAL A 120;LEU A 189;ALA A 199","None","0.99A","6hd4A-6c9dA:21.0","6hd4A-6c9dA:24.18"],["6HD4_A_STIA604_0","6cmj","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",7,"VAL A 179;ALA A 192;LYS A 194;GLU A 236;VAL A 249;LEU A 319;ALA A 329","F6J A 501 (-4.6A);F6J A 501 (-3.4A);F6J A 501 (-2.9A);F6J A 501 ( 4.7A);None;F6J A 501 (-4.5A);F6J A 501 ( 4.0A)","0.89A","6hd4A-6cmjA:22.0","6hd4A-6cmjA:19.28"],["6HD4_A_STIA604_0","6fyl","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK2","no annotation",7,"VAL A 177;ALA A 191;GLU A 208;ILE A 215;ILE A 241;LEU A 297;ASP A 327","3NG A 501 ( 4.4A);3NG A 501 (-3.3A);3NG A 501 ( 4.9A);None;None;None;3NG A 501 (-4.5A)","1.20A","6hd4A-6fylA:7.3","6hd4A-6fylA:undetectable"],["6HD4_A_STIA604_0","6fyl","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK2","no annotation",7,"VAL A 177;ALA A 191;GLU A 208;VAL A 227;ILE A 241;LEU A 297;ASP A 327","3NG A 501 ( 4.4A);3NG A 501 (-3.3A);3NG A 501 ( 4.9A);None;None;None;3NG A 501 (-4.5A)","1.03A","6hd4A-6fylA:7.3","6hd4A-6fylA:undetectable"],["6HD4_A_STIA604_0","6fyl","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK2","no annotation",7,"VAL A 177;ALA A 191;LYS A 193;GLU A 208;ILE A 215;ILE A 241;LEU A 297","3NG A 501 ( 4.4A);3NG A 501 (-3.3A);3NG A 501 (-3.0A);3NG A 501 ( 4.9A);None;None;None","1.01A","6hd4A-6fylA:7.3","6hd4A-6fylA:undetectable"]]